Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeutics, says Fact. ROCKVILLE , MD, UNITED STATES, December 13 ...

The program provides an educational environment for fellows to develop a comprehensive understanding of the pathophysiology of pediatric hematologic and oncologic disorders and excellence in the ...

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

We aspire to cultivate a culture of well-being, collegiality, and positivity to promote academic pursuit. This broad-based educational opportunity explores all aspects of solid tumors and malignant ...

While ex vivo modification of hematopoietic stem cells is being primarily developed to target genetic diseases of the blood such as hemoglobinopathies and immune deficiencies, it also has great ...

The posters, both addressing zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) – a rare, life-threatening hematological disorder – detail positive Phase 2 clinical data and clinical ...